GOSSAMER BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.694 USD | -4.93% |
|
-6.51% | -23.95% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Gossamer Bio TORREY ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Calendar
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
0.694
USD
Average target price
6.094
USD
Spread / Average Target
+778.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.95% | 165M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- GOSS Stock
- News Gossamer Bio, Inc.
- Transcript : Gossamer Bio, Inc. - Special Call
